Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine
AUTOR(ES)
Gupta, Sunil Kumar; Kumari, Sushantika
FONTE
Anais Brasileiros de Dermatologia
DATA DE PUBLICAÇÃO
2022
RESUMO
Abstract Erythema nodosum leprosum is a severe immune reaction that complicates the usual course of multibacillary leprosy. There is increased activation of T-cells in erythema nodosum leprosum. Treatment modalities available to date for the management are systemic steroids, thalidomide, methotrexate, cyclophosphamide, azathioprine, minocycline, and apremilast but none of them is promising and safe. Mycobacterium indicus pranii is an atypical mycobacterium possessing strong immunomodulatory properties. The vaccine for this mycobacterium has been shown to have both immunotherapeutic and immunoprophylactic effects in multibacillary leprosy patients. We report a case of chronic recalcitrant erythema nodosum Leprosum which responded to Mycobacterium indicus pranii vaccine without any adverse effects, thereby suggesting its role as a novel therapeutic option in this reaction.
Documentos Relacionados
- Etanercept in erythema nodosum leprosum
- Critical residues of the Mycobacterium leprae LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions.
- Polymorphonuclear cell function in the various polar types of leprosy and erythema nodosum leprosum.
- Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum.
- Infection of the lymphatic system by Aureobasidium pullulans in a patient with erythema nodosum leprosum